Hepa-Merz 10 Sachets

Hepa-Merz is a medication containing the active ingredient L-Ornithine L-Aspartate (LOLA) at a dose of 3 g per sachet of granules for oral solution. It works by enhancing the elimination of ammonia in the body through supporting its conversion into urea in the liver, as well as promoting its clearance in extrahepatic tissues. It is primarily used to treat disorders associated with impaired hepatic detoxification, such as liver cirrhosis accompanied by latent or overt hepatic encephalopathy.

What is the use of Hepa-Merz sachet?

• Helps promote the elimination of ammonia in the body.

• Contributes to supporting the urea cycle in the liver, aiding in the conversion of ammonia to urea for excretion.

• Helps reduce elevated ammonia levels associated with impaired liver function.

• Used as part of the treatment for disorders associated with or resulting from impaired hepatic detoxification capacity.

• Used in cases of latent and overt hepatic encephalopathy associated with liver diseases, such as cirrhosis.

• Contains a combination of two amino acids, L-ornithine and L-aspartate, in a stable salt form.

Hepa-Merz dose

• Usual Dosage: Unless otherwise prescribed by a physician, take 1–2 sachets up to 3 times daily.

• Dissolve the contents of the sachet in a sufficient amount of liquid, such as a glass of water, tea, or juice.

• Preferably taken during or after meals.

• Strictly adhere to the dosage specified by the doctor based on the patient's condition and liver and kidney function.

• Should not be used in children except under medical supervision, due to limited data available regarding its use in this age group.

Precautions and Warnings

• Do not use in case of known hypersensitivity to L-Ornithine L-Aspartate or any inactive ingredients.

• Contraindicated in individuals with severe renal impairment (a serum creatinine level exceeding 3 mg/100 ml serves as a reference threshold).

• Consult a doctor before use in patients with liver or kidney disease.

• Contains fructose; therefore, it is unsuitable for individuals with hereditary fructose intolerance or certain carbohydrate metabolic disorders.

• May contain aspartame (E951), a source of phenylalanine, and should be avoided by individuals with phenylketonuria (PKU).

• Consult a physician prior to use during pregnancy or breastfeeding, as sufficient clinical data for these periods are lacking.

• Hepatic encephalopathy itself may impair the ability to drive or operate machinery; follow medical guidance regarding these activities.

Side Effects

Possible side effects may include:

• Nausea.

• Vomiting.

• Stomach pain or discomfort.

• Abdominal bloating.

• Diarrhea.

• Rarely, pain in the limbs.

Gastrointestinal symptoms are usually temporary and rarely require discontinuation of treatment; reducing the dose may help mitigate them. Allergic reactions may occur in individuals sensitive to any component, including Sunset Yellow (E110).

Storage and Handling

• Store below 25°C.

• Store in a dry place away from moisture.

• Keep out of reach of children.

• Store in the original packaging until time of use.

• Do not use after the expiration date printed on the package.

Ingredients

• Active Ingredient: L-Ornithine L-Aspartate: 3 g per sachet.

• Inactive Ingredients: Citric acid, fructose, povidone K25, flavorings, and Sunset Yellow FCF (E110). May also contain aspartame (E951) or sodium saccharin and sodium cyclamate, depending on the formulation version.